The Most Trusted Name in Securities Class Action Law

Over $400 million recovered for investors in the last 2 years

Enochian Biosciences, Inc.

On May 25, 2022, during trading hours, the U.S. Department of Justice (DOJ) announced that Serhat Gumrukçu, the inventor and co-founder of Enochian BioSciences, had

Read More

HUTCHMED (China) Limited

On May 2, 2022, before trading hours, HUTCHMED announced that the U.S. Food and Drug Administration (FDA) rejected HUTCHMED’s application seeking approval of surufatinib to

Read More

Carvana Co.

On May 18, 2022, the Illinois Secretary of State’s office announced that Carvana’s license to sell vehicles in Illinois was suspended on May 10 due

Read More

HUMBL, LLC

According to the lawsuit, defendants violated provisions of the Exchange Act by making false and misleading statements concerning the Company’s growth prospects, technological advancements, international

Read More

Inotiv, Inc.

On May 20, 2022, after the market closed, Inotiv filed with the SEC a current report on Form 8-K which disclosed that “the U.S. Department

Read More

CareDx, Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: defendants had engaged in a variety

Read More

Enservco Corporation

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Enservco had defective disclosure controls and

Read More

Okta, Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Okta had inadequate cybersecurity controls; as

Read More

Pegasystems Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: PEGA had engaged in corporate espionage

Read More

Enochian Biosciences, Inc.

On May 25, 2022, during trading hours, the U.S. Department of Justice (DOJ) announced that Serhat Gumrukçu, the inventor and co-founder of Enochian BioSciences, had

Read More

HUTCHMED (China) Limited

On May 2, 2022, before trading hours, HUTCHMED announced that the U.S. Food and Drug Administration (FDA) rejected HUTCHMED’s application seeking approval of surufatinib to

Read More

Carvana Co.

On May 18, 2022, the Illinois Secretary of State’s office announced that Carvana’s license to sell vehicles in Illinois was suspended on May 10 due

Read More

HUMBL, LLC

According to the lawsuit, defendants violated provisions of the Exchange Act by making false and misleading statements concerning the Company’s growth prospects, technological advancements, international

Read More

Inotiv, Inc.

On May 20, 2022, after the market closed, Inotiv filed with the SEC a current report on Form 8-K which disclosed that “the U.S. Department

Read More

CareDx, Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: defendants had engaged in a variety

Read More

Enservco Corporation

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Enservco had defective disclosure controls and

Read More

Okta, Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Okta had inadequate cybersecurity controls; as

Read More

Pegasystems Inc.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: PEGA had engaged in corporate espionage

Read More

Digital Turbine, Inc.

On May 17, 2022, Digital Turbine issued a press release “announc[ing] . . . that it will restate its financial statements for the interim periods

Read More

Allianz SE

On August 1, 2021, Allianz disclosed that “[s]ubsequent to the litigation pending in U.S. courts in relation to the Structured Alpha Funds against Allianz Global

Read More

Upstart Holdings, Inc.

According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: Upstart’s AI model could not adequately account for macroeconomic factors

Read More

Oscar Health, Inc.

According to the lawsuit, the IPO Registration Statement was materially false and misleading and omitted to state: Oscar was experiencing growing COVID-19 testing and treatment

Read More

MEI Pharma, Inc.

On May 13, 2022, after market hours, MEI Pharma announced restatements of its financial statements for certain quarters for 2020 and 2021. In part, MEI

Read More

Our Mission

The Rosen Law Firm, P.A. is dedicated to recovering damages for shareholders victimized by corporate fraud and other misconduct. Our attorneys have a wealth of knowledge and experience handling complex financial litigation and winning significant victories and settlements for our clients. By focusing exclusively on securities class actions and derivative litigation, we have risen to the forefront of plaintiffs’ firms and have recovered damages totaling hundreds of millions of dollars for our clients. Our mission is to protect shareholders rights.

In the News

FAQ

Class actions are lawsuits where one or more investors serve as the representative plaintiffs on behalf of a large group of investors that each purchased the same securities and suffered losses as a result of the same false statements or misconduct.  Class actions allow a court to decide the claims of many investors in a single lawsuit. This promotes efficiency, economy, and extends justice to investors whose claims are not large enough to merit an individual lawsuit.

This is the time period during which investors purchased securities in the company that is the subject of the class action.  Typically, the false statements or fraud begin on the first day of the class period and the full truth about the false statements or fraud is revealed on the last day of the class period.

A lead plaintiff is an investor that wishes to serve as a representative plaintiff in the class action on behalf of all the other investors that purchased securities during the Class Period.

The Lead Plaintiff’s role is to oversee the litigation with the assistance and advice of the class’s attorneys. Both the Lead Plaintiff and the class’s attorneys must direct the litigation for the benefit of the class foremost. Ultimately, it is the job of the Lead Plaintiff to decide what is a fair settlement amount for the Class and to approve any settlement offer.

Lead Counsel are the Class’s attorneys.  The Lead Plaintiff selects the Lead Counsel.  Lead Counsel should have extensive experience prosecuting securities class actions if they are to effectively represent investors in a securities class action. 

If the amount of your losses in the investment are significant to you, being a lead plaintiff allows you to be involved in the case and oversee important decisions in the litigation, particularly the amount of any settlement for investors.

Class action lawsuits often are filed when it would be impractical or prohibitively expensive for each person who was harmed to file an individual lawsuit, and they enable small shareholders or consumers to seek recovery from large corporations possessing much greater legal and financial resources. Generally, securities class actions are filed in the Federal District Courts and allege that the defendant(s) violated the Securities Act of 1933 and/or the anti-fraud provisions of the Securities Exchange Act of 1934. The typical class action takes at least 2-3 years to litigate, although the actual time it takes to resolve a case varies, depending on the complexity of the case, the issues involved, and other factors.

You can complete the online certification form on our website or at your request, we will email you a form to complete and you can send it back to us.

You do not pay any legal fees, costs or expenses. The Court will award the Lead Counsel any legal fees, costs or expenses from the money they recover for the class. If Lead Counsel doesn’t recover any money for the class, Lead Counsel doesn’t get paid any legal fees, costs or expenses.

Our Offices

New York

275 Madison Avenue,

40th Floor
New York, NY 10016
T: 212.686.1060
F: 212.202.3827

Los Angeles

355 South Grand Avenue, Suite 2450
Los Angeles, CA 90071
T: 213.785.2610
F: 213.226.4684

Philadelphia Metro

101 Greenwood Avenue,

Suite 440
Jenkintown, PA 19046
T: 215.600.2817

F: 212.202.3827

New Jersey

One Gateway Center,

Suite 2600
Newark, NJ 07102
T: 973.313.1887
F: 973.833.0399

Get a Free Consultation

Email us at info@rosenlegal.com 

The Rosen Law Firm is dedicated exclusively to recovering investment losses for investors in companies that have misrepresented material aspects of their business or whose officers and directors have breached their fiduciary duties to shareholders.

Scroll to Top